Skip to main content
Christian Maurer on Muck Rack

Christian Maurer

As seen in: Nature, Taylor & Francis Online, Tagesschau, Blick, Tages Anzeiger, Basler Zeitung, Texas Medical Center, Der Bund, Springer Professional, Der Landbote and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christian

Contact Christian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry

|
By Andreas Hartkopf, Nelson John, Philipp A. Ziegler, Lothar Häberle, Chloë Goossens, Jan-Philipp Cieslik, Dominik Dannehl, Thomas Deutsch, Moritz Dimpfl, Melitta B. Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Nikolas Tauber, Christian M. Tegeler, Maggie Banys-Paluchowski, Achim Rody, Sara Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Peyman Hadji, Alexander Ochoa Hein, Wolfgang Janni, Hans-Christian Kolberg, Diana Lüftner, Michael Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch, Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Laura Michel, Markus Wallwiener, Andreas Schneeweiss, Christian Maurer, Manuel Hörner, Sabrina Uhrig, Niklas Amann, Lara M. Tretschock, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Lea Sych, Catharina Wichmann, Henriette Princk, Erik Belleville
| Nature Verified
Abstract Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their routine clinical use highlights the importance of this analysis.
Open in Who Shared Issue with article?

Association of Statin Use on Survival Outcomes of Patients With Early-Stage HER2-Positive Breast Cancer in the APHINITY Trial

|
By Christian Maurer
| Texas Medical Center
Breast Cancer Research and Treatment 10.1007/s10549-025-07699-2 Post-print Humans, Female, Breast Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Middle Aged, Receptor, ErbB-2, Aged, Neoplasm Staging, Adult, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Trastuzumab, Kaplan-Meier Estimate, Prognosis, Breast cancer, HER2-positive, Statins, Pertuzumab, Trastuzumab yes Maurer, Christian; Agostinetto, Elisa; Ameye, Lieveke; et al., "Association of Statin Use on...
Open in Who Shared Issue with article?

Nichtsequentielle und Verteilte Programmierung mit Go

|
By Christian Maurer
| Springer Professional
Dieses Buch führt nach einem kurzen Kapitel über grundlegende Aspekte der Softwaretechnik und deren Realisierung in Go in die Nichtsequentielle und Verteilte Programmierung mit Go ein. Es stellt grundlegende Konzepte zur Synchronisation und Kommunikation nebenläufiger Prozesse systematisch dar.
Open in Who Shared Issue with article?
See all 150 articles